Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Discover yearly leaders among index funds and understand how performance shifts across periods, helping you choose resilient options.
27,236 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A four-year tax window under SECURE 2.0 lets workers aged 60-63 contribute up to $11,250 a year to a 401(K). Surgeons...
A 67-year-old retiree can add roughly $50,000 a year from self-employment without reducing Social Security benefits, ...
Price dips in tech stocks can hide real strength. This article explains why a stock with improving fundamentals might...
Energy Select Sector SPDR Fund (XLE) has staged a rebound as crude hits higher levels. Two key signals could set the ...
Could Palantir move higher over the next year? This guide breaks down three realistic scenarios, key catalysts, and p...
Bitwise argues that investors have not fully priced Hyperliquid's expansion into a multi-asset platform and the value...
MSG Sports’ stock has surged as the Knicks clawed into the NBA Finals, signaling a rare windfall for investors bettin...
An affluent California couple in their 70s plans a major renovation. Months later, they confront a surprising, steep ...
Fortune Brands stock down 24% has drawn fresh attention after a major investor disclosed a $113 million stake in Fort...
As NIU gears up for the (niu) 2025 earnings call, investors want clarity on future growth, margins, and strategic bet...
Investors face a pivotal choice: put $10,000 into Nvidia's AI compute surge or Meta's ad-driven AI expansion. Here's ...